Fibrocor Therapeutics
Fibrocor and Galapagos Sign Expanded Collaboration in Fibrosis
Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor.
Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. To date, the company has successfully identified a suite of novel targets in fibrosis through ...
Read more
Fibrocor Therapeutics enters deal with Galapagos NV
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs.
In 2017 MaRS Innovation founded, and subsequently seed-funded, Fibrocor. The company is based on research from two of MaRS Innovation’s Member institutions, St. Michael’s Hospital and Sinai Health Systems – specifically, from the labs of Drs. Richard ...
Read more
Fibrocor Therapeutics Appoints Its First CEO
Toronto, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics (Fibrocor) announced today that Mark Steedman has been appointed as its first president and CEO, and will serve as a member of Fibrocor’s board of directors.
Mr. Steedman is the co-founder of Interface Biologics where he most recently served as VP, Business Development. He was responsible for all start-up operations including financing and business development up to Series A totaling $13M, and was instrumental in early transactions with large multinational corporations, which ultimately led ...
Read more